NEW YORK |
Reuters Health) -
Men who are treated for prostate cancer with hormone-targeted therapy
have a higher risk of developing kidney problems, a new study suggests.
The treatment, known as
androgen deprivation therapy, lowers the risk of death among men with
advanced, aggressive prostate cancer.
However,
researchers said it's increasingly being used to treat possible
recurrences among men with less advanced disease - for whom the benefits
are less clear, and the risks more worrisome.
Read the full Reuters Health report
